Hong Kong Investment Corporation (HKIC)

Strategic development fundCore national fund

The Hong Kong Investment Corporation (HKIC) is the Government's patient capital investor, set up in 2022 with HK$62 billion to deploy.

香港投資管理有限公司 · Hong Kong SAR, China · Asia · Founded 2022 · Strategic development fund · Not an IFSWF memberData confidence: Medium · 9 sources

What it invests in
Data table
SectorsTechnology; Healthcare and life sciences; Renewables and climate; Industrials and manufacturing; Financial services
StagesVenture; Growth
GeographyDomestic and global: Hong Kong, Greater Bay Area, Mainland China, Belt and Road
How big it is
Data table
Headline sizeHK$62B
BasisCommitted or authorised capital
As of2026-10-05
What it publishes
Data table
Total assetsPublished
Annual returnPartly published
Long-term returnsPartly published
Asset allocationPartly published
Geographic or sector splitPartly published
Holdings or deal listPartly published
Audited financial statementsNot published
Governance and mandate documentsPartly published
Named leadershipPublished
Regular reporting schedulePublished

HKIC: what it invests in

HKIC sectors: Technology, Healthcare and life sciences, Renewables and climate, Industrials and manufacturing, Financial services. Stages: Venture, Growth. Geography: Domestic and global.
SectorsTechnology; Healthcare and life sciences; Renewables and climate; Industrials and manufacturing; Financial services
StagesVenture; Growth
GeographyDomestic and global: Hong Kong, Greater Bay Area, Mainland China, Belt and Road

Sources

  1. S2HKSAR Government, LegCo question reply on HKIC, 16 April 2025
  2. S1HKIC, Annual Report 2025 release, 16 July 2026
  3. S7HKIC, CEO speech at BioHK 2025 AI Sub-Forum, 10 September 2025
  4. S4Hong Kong Investment Corporation, Home

HKIC: how big it is, and on what basis

HKIC headline size HK$62B, basis Committed or authorised capital.
Headline sizeHK$62B
BasisCommitted or authorised capital
As of2026-10-05

Sources

  1. S4Hong Kong Investment Corporation, Home
  2. S1HKIC, Annual Report 2025 release, 16 July 2026

HKIC: what it publishes

HKIC transparency score 6.0 of 10 across 10 published items.
Total assetsPublished
Annual returnPartly published
Long-term returnsPartly published
Asset allocationPartly published
Geographic or sector splitPartly published
Holdings or deal listPartly published
Audited financial statementsNot published
Governance and mandate documentsPartly published
Named leadershipPublished
Regular reporting schedulePublished

Sources

  1. S4Hong Kong Investment Corporation, Home
  2. S1HKIC, Annual Report 2025 release, 16 July 2026
  3. S2HKSAR Government, LegCo question reply on HKIC, 16 April 2025
  4. S9Legislative Council Panel on Financial Affairs, HKIC briefing, 1 June 2026
  5. S6HKSAR Government, HKIC CEO reappointment, 2 October 2026
  6. S8The Standard, HKIC logs HK$6.4b investment income in 2025
Initial capitalS4
HK$62B (about USD 8.0B)
Projects, June 2026S1
200+
As of
Net IRR, end 2025S1
14%
As of
Investment income 2025S1
HK$6.4B (up about 175%)
As of
Capital multiplierS1
HK$1 to HK$8+ (outside capital per HK$1)
As of
Listed in Hong KongS6
11 companies (October 2026)
As of

Overview

At a glance. The Hong Kong Investment Corporation (HKIC) is the Government's patient capital investor, set up in 2022 with HK$62 billion to deploy. It backs hard and core technology, biotech and green technology companies that commit to building in Hong Kong. By June 2026 it had invested in over 200 projects, reported a 14 percent net IRR at end 2025 and drew over HK$8 of outside capital for each HK$1. S4 S1

Key points

  • HK$62 billion of initial capital across four pools: Hong Kong Growth Portfolio, GBA Investment Fund, Strategic Tech Fund and Co-Investment Fund. S4
  • Over 200 projects by June 2026, up from about 100 in March 2025 and over 130 in September 2025. S1 S2 S7
  • Net IRR of 14 percent at end 2025; investment income over HK$6.4 billion in 2025, up about 175 percent. S1
  • Capital split in April 2025: hard and core tech 56 percent, biotech and health tech 16, new energy and green tech 11. S2
  • 11 portfolio companies listed in Hong Kong by October 2026; over 30 applied or preparing to apply. S6 S1
  • Investees must open offices and R&D in Hong Kong and favour a Hong Kong listing. S2
  • An offshore RMB venture capital fund is being set up to back Chinese tech going global. S1

Interesting facts

  • Each project averaged two to three investing institutions alongside HKIC in early 2025. S2
  • Insilico Medicine is co-launching an AI drug discovery incubator giving HKIC first look at its projects. S7
  • HKIC ran with 53 staff positions across four departments in April 2025. S2

Mandate and goals

A dual mission: a reasonable medium to long-term financial return from fiscal reserves, and using that capital to build Hong Kong's innovation ecosystem and industry chains under an "Investment +" approach. S5 S1

  • Earn reasonable returns over the medium to long term. S4
  • Draw companies and long-term capital to Hong Kong. S2 S1
  • Back platform projects that lift the wider ecosystem. S4

How it invests

IndustriesTechnology, Healthcare and life sciences, Renewables and climate, Industrials and manufacturing, Financial services S2 S1
Asset classesVenture capital, Private equity, Private credit S2
StagesVenture, Growth S2 S7
GeographyDomestic and global. Companies rooted in or moving to Hong Kong, many from the mainland and expanding overseas S1
Direct / through funds / co-investYes / Yes / Yes S2
Ticket sizeDeal sizes are not disclosed. S2
External managersSome capital via funds and co-investment partners; external experts for due diligence S2
Co-investment programmeCo-Investment Fund; overseas sovereign funds and pension plans co-invest alongside HKIC S1

Published criteria

  • Companies commit to Hong Kong offices, R&D or corporate venture units, and a preference for a Hong Kong listing. S2
  • Priority to platform projects that benefit other ecosystem partners. S4
  • Underwriting on a par with professional institutional investors. S7

Past investments

YearInvestmentTypeSectorStageAmount
2025Insilico Medicine. AI drug discovery; investment plus strategic partnership and the Longevity Frontier Space incubator. S7 S8Direct investmentHealthcare and life sciencesGrowthNot disclosed
2024Galbot. Embodied AI robots; HKIC-led embodied AI talent centre with Hong Kong universities. S5 S9Direct investmentTechnologyVentureNot disclosed
Not publishedEcoCeres. Hong Kong sustainable aviation fuel developer; third plant planned in Dongguan. S9 S8Direct investmentRenewables and climateGrowthNot disclosed
Not publishedMoonshot. AI large language models. S8Direct investmentTechnologyVentureNot disclosed
Not publishedAgibot. Humanoid and embodied AI robotics. S9Direct investmentTechnologyVentureNot disclosed
Not publishedSmartMore. Industrial AI and machine vision. S9Direct investmentTechnologyVentureNot disclosed
Not publishedEmaldo. AI home battery storage and energy management. S8Direct investmentRenewables and climateVentureNot disclosed

Case studies

Insilico Medicine: Investment + S7

What
Invested in the AI drug discovery company and agreed a strategic partnership tied to Hong Kong commitments.
When
2025
Size
Not published
Why
Anchor a biotech platform in Hong Kong that can seed more companies.
Outcome
Insilico is setting up an AI drug discovery incubator in Hong Kong with first-look rights for HKIC.

Galbot and embodied AI S5

What
Backed the robotics company and led an ecosystem plan for its Hong Kong base.
When
2024
Size
Not published
Why
Make Hong Kong a hub for embodied AI research and talent.
Outcome
An International Embodied AI Talent Exchange Center with Hong Kong universities.

Investment process

All investments are approved by the Board or its investment committee. The Board, chaired by the Financial Secretary, includes policy bureau officials and non-official industry leaders. S2 S6

CommitteeRole
Board of DirectorsChaired by the Financial Secretary; sets strategy and approves investments S2
Investment CommitteeApproves investments under delegation S2
  1. Theme-led sourcing across hard tech, biotech and green tech. S2
  2. Due diligence with outside experts. S2
  3. Deal structure, Hong Kong commitments and exit terms set per project. S2
  4. Board or investment committee approval. S2
  5. Post-deal support with partners, scenarios and capital. S1

How to approach: HKIC lists a contact page on its website; no open application programme is published. S4

Size and returns

  • Headline size: HK$62B (Committed or authorised capital) S4
  • In US dollars: about USD 7.96B. Initial capital for deployment at HK$7.7842 per USD (31 December 2025); not a net asset value
  • Investment income 2025: HK$6.4B (Published estimate, as of 2026-07-16) S1
  • Return, since inception to end 2025: 14.0 percent a year (net IRR of the investment portfolio) S1

Leadership

NameTitleSince
Clara ChanChief Executive Officer S62023-10
Paul Chan Mo-poFinancial Secretary; Chairman of the Board S6Not published

Governance and transparency

  • Legal basis: Company wholly owned by the Hong Kong SAR Government, announced in the 2022 Policy Address S4 S1
  • Oversight: Board chaired by the Financial Secretary; briefings to the Legislative Council S2 S9
  • First annual report, for 2025, released in July 2026. S1
  • CEO reappointed for three years from 9 October 2026. S6

Transparency score: 6.0 of 10 (band 3 of 5). Our own 10-item rubric; see the methodology page.

  • Published: total assets, named leadership, regular reporting schedule. S1 S4 S6
  • Partly published: annual return, long-term returns, asset allocation, geographic or sector split, holdings or deal list, governance and mandate documents. S1 S2 S8
  • Not published: audited financial statements. S1

History

DateEvent
2022Policy Address announces HKIC. S1
2023-10Clara Chan appointed first CEO. S6
2024-07Galbot ecosystem plan launched. S5
2025-03About 100 projects. S2
2025-09Over 130 projects; Insilico partnership. S7
2026-07-16First annual report; over 200 projects. S1
2026-10-09CEO starts second three-year term. S6

For family offices

HKIC co-invests with other institutions and reports over HK$8 of outside capital per HK$1, but has no published family office programme. S1 S2

  • Co-investment alongside sovereign funds, pension plans and other long-term investors. S1
  • Introductions to industry partners and application scenarios for portfolio companies. S1

Reports

Common questions

How large is HKIC?

HK$62 billion of initial capital for deployment. S4

How has it performed?

Net IRR of 14 percent at end 2025 and over HK$6.4 billion of investment income in 2025. S1

What does it require of investees?

A real Hong Kong presence, such as offices and R&D, and a preference for listing in Hong Kong. S2

Who runs it?

CEO Clara Chan; the Financial Secretary chairs the Board. S6

Compare with similar funds

FundCountryTypeSizeTransparencyDeals listed
HKIC
This fund
Hong Kong SAR, ChinaStrategic development fundHK$62B6.02
Indonesia Investment AuthorityIndonesiaStrategic development fundRp111.0tn9.08
China-Africa Development Fund (CADFund)ChinaStrategic development fundUSD 10B fund scale2.510
National Investment and Infrastructure Fund (NIIF), IndiaIndiaStrategic development fundUSD 5B+6.09
CNIC Corporation LimitedHong Kong SAR, ChinaStrategic development fundUSD 11.1B capital1.57
Maharlika Investment Corporation (MIC)PhilippinesStrategic development fundPHP 128.23B6.56

All sovereign wealth funds in Asia · All strategic development funds · All funds in Hong Kong SAR, China

Read next

Compare and lists: CNIC vs HKIC · Future Fund (Hong Kong SAR, China) vs HKIC · Sovereign wealth funds funded by fiscal surpluses · Sovereign wealth funds investing in financial services in Asia · Sovereign wealth funds investing in healthcare and life sciences in Asia · Sovereign wealth funds investing in industrials and manufacturing in Asia · Sovereign wealth funds investing in renewables and climate in Asia · Sovereign wealth funds investing in technology in Asia · Sovereign wealth funds that co-invest in Asia · Sovereign wealth funds that invest at the venture stage · Sovereign wealth funds that invest at the growth stage · Sovereign wealth funds that invest in private credit in Asia · Sovereign wealth funds that co-invest · Sovereign wealth funds that invest in private equity in Asia · Sovereign wealth funds that invest in private credit · Sovereign wealth funds that invest in private equity · Sovereign wealth funds that invest in venture capital · Sovereign wealth funds that invest through private funds in Asia · Sovereign wealth funds that invest in venture capital in Asia · Sovereign wealth funds that use external managers in Asia · Sovereign wealth funds that invest through private funds · Sovereign wealth funds that use external managers

Sources

9
  1. S1HKIC, Annual Report 2025 release, 16 July 2026
  2. S2HKSAR Government, LegCo question reply on HKIC, 16 April 2025
  3. S3IFSWF, Our members
  4. S4Hong Kong Investment Corporation, Home
  5. S5HKIC, HKIC and GALBOT collaborate on Hong Kong ecosystem augmentation
  6. S6HKSAR Government, HKIC CEO reappointment, 2 October 2026
  7. S7HKIC, CEO speech at BioHK 2025 AI Sub-Forum, 10 September 2025
  8. S8The Standard, HKIC logs HK$6.4b investment income in 2025
  9. S9Legislative Council Panel on Financial Affairs, HKIC briefing, 1 June 2026

Disclaimer

Informational only. SovereignWealthFunds.com is an independent public-source reference. It is not affiliated with or endorsed by any fund named on it, and it is not investment, legal or tax advice. Figures are as of the dates shown next to them and may have changed; please read each fund's official pages, linked on its profile. To report an error, use the contact page. Copyright SovereignWealthFunds.com. All rights reserved.

Richard C. Wilson

Talk to Richard.

I'm Richard C. Wilson, founder of Family Office Club. I read the messages that come in through this site myself. Text or WhatsApp me at (808) 600-9260, or email richard@familyoffices.com. Thank you.

Tell me your situation